MCL1 and diffuse large B-cell lymphoma: Analysis of primary DLBCL patient samples treated with BH3 mimetic drugs (BCL-2 inhibitor and MCL-1 inhibitor) showed that patients could be subdivided into BCL-2-sensitive or MCL-1-sensitive subgroups [10].